Matrix metalloproteinases in vascular physiology and disease

Vascular

Volumn 20, Issue 4, 2012, Pages 210-216

  Siefert, Suzanne A ^a   Sarkar, Rajabrata ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Aneurysm; Angiogenesis; Arteriogenesis; Atherosclerosis; Extracellular matrix; Ischemia; Matrix metalloproteinase

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ABDOMINAL AORTA ANEURYSM; ANEURYSM; ANGIOGENESIS; ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; GENE EXPRESSION; HUMAN; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE;

ANEURYSM; ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; EXTRACELLULAR MATRIX; HUMANS; HYPERPLASIA; MATRIX METALLOPROTEINASES; NEOINTIMA; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR DISEASES;

EID: 84866183545     PISSN: 17085381     EISSN: 1708539X     Source Type: Journal    
DOI: 10.1258/vasc.2011.201202     Document Type: Review

References (55)

1. Gross J. How tadpoles lose their tails: path to discovery of the first matrix metalloproteinase. Matrix Biol 2004;23:3-13 (Pubitemid 38686713)
2. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962;48:1014-22
3. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008;29:258-89
4. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67
5. Tallant C, Marrero A, Gomis-Ruth FX. Matrix metalloproteinases: fold and function of their catalytic domains. Biochim Biophys Acta 2010;1803:20-8
6. Stocker W, Bode W. Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr Opin Struct Biol 1995:5:383-90
7. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625-37 (Pubitemid 34628725)
8. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4 (Pubitemid 129519680)
9. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995;375:244-7
10. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516 (Pubitemid 33096184)
11. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-85
12. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-83 (Pubitemid 30119906)
13. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010;1803:55-71
14. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000;97:4052-7 (Pubitemid 30226085)
15. Vu TH, Shipley JM, Bergers G, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998;93:411-22 (Pubitemid 28232085)
16. Hobeika MJ, Edlin RS, Muhs BE, Sadek M, Gagne PJ. Matrix metalloproteinases in critical limb ischemia. J Surg Res 2008;149:148-54
17. Lee JG, Dahi S, Mahimkar R, et al. Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia. Proc Natl Acad Sci USA 2005;102:16345-50 (Pubitemid 41688916)
18. Muhs BE, Gagne P, Plitas G, Shaw JP, Shamamian P. Experimental hindlimb ischemia leads to neutrophil-mediated increases in gastrocnemius MMP-2 and -9 activity: a potential mechanism for ischemia induced MMP activation. J Surg Res 2004;117:249-54 (Pubitemid 38393650)
19. Huang PH, Chen YH, Wang CH, et al. Matrix metalloproteinase-9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2009;29:1179-84
20. Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 2004;94:262-8 (Pubitemid 38197460)
21. Cheng XW, Kuzuya M, Nakamura K, et al. Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2-deficient mice. Circ Res 2007;100:904-13 (Pubitemid 46555696)
22. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44
23. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95 (Pubitemid 30208155)
24. Mu D, Cambier S, Fjellbirkeland L, et al. The integrin alpha(v) beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol 2002;157:493-507 (Pubitemid 34839812)
25. Xu J, Rodriguez D, Petitclerc E, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001;154:1069-79 (Pubitemid 34286185)
26. Mangai M, Kitaya N, Xu J, et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 2002;161:1429-37
27. Ardi VC, Kupriyanoca TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007;104:20262-7
28. Ulrich D, Lichtenegger F, Unglaub F, Smeets R, Pallua N. Effect of chronic wound exudates and MMP-2/-9 inhibitor on angiogenesis in vitro. Plast Reconstr Surg 2005;11:539-45 (Pubitemid 41077210)
29. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 2003;100:4766-71 (Pubitemid 36457804)
30. Grundmann S, Piek JJ, Pasterkamp G, Hoefer IE. Arteriogenesis: basic mechanisms and therapeutic stimulation. Eur J Clin Invest 2007;37:755-66 (Pubitemid 47480848)
31. Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006;10:45-55 (Pubitemid 44874291)
32. Mason DP, Kenagy RD, Hasensta D, et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res 1999;85:1179-85 (Pubitemid 30430623)
33. Cai WJ, Koltai S, Kocsis E, et al. Remodeling of the adventitia during coronary arteriogenesis. Am J Physiol Heart Circ Physiol 2003;284:H31-40 (Pubitemid 36076267)
34. Sho E, Sho M, Singh TM, et al. Arterial enlargement in response to high flow requires early expression of matrix metalloproteinases to degrade extracellular matrix. Exp Mol Pathol 2002;73:142-53
35. Abbruzzese TA, Guzman RJ, Martin RL, Yee C, Zarins CK, Dalman RL. Matrix metalloproteinase inhibition limits arterial enlargements in a rodent arteriovenous fistula model. Surgery 1998;124:328-34; discussion 334-5
36. Lin CC, Yang WC, Chung MY, Lee PC. Functional polymorphisms in matrix metalloproteinases-1, -3, -9 are associated with arteriovenous fistula patency in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1805-14
37. Aikawa M, Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998;97:2433-44 (Pubitemid 28278188)
38. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995;748:501-7
39. Tanindi A, Sahinarsian A, Elbeg S, Cemri M. Association of matrix metalloproteinase-1, matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1, and interleukin-6 with epicardial and myocardial perfusion. Coron Artery Dis 2011;22:253-8
40. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006;97:175-80 (Pubitemid 43139231)
41. Amorino GP, Hoover RL. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol 1998;152:199-207 (Pubitemid 28028060)
42. Hojo Y, Ikeda U, Takahashi M, et al. Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells. Mol Cell Cardiol 2000;32:1459-68
43. Zhu Y, Hojo Y, Ikeda U, Takahashi M, Shimada K. Interaction between monocytes and vascular smooth muscle cells enhances matrix metalloproteinase-1 production. J Cardiovasc Pharmacol 2000:36:152-61 (Pubitemid 30659834)
44. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995;92:402-6
45. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995;91:2125-31
46. Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ. Matrix metalloproteinases in peripheral vascular disease. J Vasc Surg 2007;45:849-57 (Pubitemid 46483940)
47. Alvarez B, Ruiz C, Chacon P, Alvarez-Sabin J, Matas M. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg 2004;40:469-75 (Pubitemid 39165021)
48. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 2006;116:59-69 (Pubitemid 43121791)
49. Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T. Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis. Interact Cardiovasc Thorac Surg 2009;9:437-40
50. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625-32 (Pubitemid 34988786)
51. Zempo N, Kenagy RD, Au YP, et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg 1994;20:209-17 (Pubitemid 24260589)
52. George SJ, Zaltsman AB, Newby AC. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res 1997;33:447-59 (Pubitemid 27072650)
53. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 2002;91:845-51 (Pubitemid 35285083)
54. Momi S, Falcinelli E, Giannini S, et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. J Exp Med 2009;206:2365-79
55. Bassiouny HS, Song RH, Hong XF, Singh A, Kocharyan H, Glagov S. Flow regulation of 72-kD collagenase IV (MMP-2) after experimental arterial injury. Circulation 1998;98:157-63 (Pubitemid 28317896)